Key result
Clozapine therapy safely continues alongside concurrent anticoagulation in a patient with recurrent PE.
Why the study?
Clozapine carries a rare but serious risk of pulmonary embolism, but managing this complication poses significant challenges due to a lack of clear guidelines for preventive anticoagulation.
Can clozapine therapy be continued with concurrent anticoagulation in patients who develop clozapine-associated pulmonary embolism?
Can clozapine therapy be continued with concurrent anticoagulation in patients who develop clozapine-associated pulmonary embolism?
This case demonstrates that clozapine therapy can be successfully continued with concurrent anticoagulation in patients who develop clozapine-associated pulmonary embolism.
May permit clozapine continuation with anticoagulation after recurrent PE; leaves open prospective trials to inform guidelines.
Clozapine, a gold standard for treatment‐resistant schizophrenia, is associated with a range of adverse effects, including the rare but serious risk of pulmonary embolism (PE). The management of such complications, particularly in the absence of clear guidelines for preventive anticoagulation, poses significant challenges. We present a case of a male (in his late 30s) with schizophrenia who developed recurrent thromboembolic events during clozapine therapy. Despite the occurrence of a second PE, clozapine therapy was continued successfully with concurrent anticoagulation. This case highlights the need for individualized treatment strategies and underscores the critical gap in evidence regarding preventive anticoagulation in patients with clozapine.
No takes yet. Share an insight, caveat, or question.
Jahangir et al. (2026) studied this question. Clozapine therapy was successfully continued alongside anticoagulation in a patient with recurrent pulmonary embolism, emphasizing the need for personalized treatment strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: